Carbon monoxide (CO) is been recently used in treatment to improve vision and is known to have positive effects, it is hypothesized as an important vascular paracrine factor and plays a role in blood flow regulation in several tissues.
Scientists say that an ingested liquid is said to ultimately deliver a small dose of carbon monoxide to the eye appears to target key factors that damage or destroy vision in both type 1 and 2 diabetes.
The Medical College of Georgia scientists have early evidence that HBI-002, a low-dose oral compound developed by Hillhurst Biopharmaceuticals and already in early stage trials for sickle cell disease, can safely reduce oxidative stress and inflammation in the retina, both early, major contributors to diabetic retinopathy.
"Inflammation and oxidative stress go hand in hand," says Dr. Pamela Martin, cell biologist and biochemist in the MCG Department of Biochemistry and Molecular Biology and Vision Discovery Institute at Augusta University. "If you impact one, you generally impact the other."
For more information check out the full story on the link below: